甲状腺功能异常治疗与血脂:系统综述与荟萃分析
该系统综述检索1970年至2018年4月MEDLINE、EMBASE、Cochrane图书馆及Scopus,纳入评估甲亢或甲减治疗前后血脂参数的随机与观察性研究。结果显示,治疗显性甲亢使TC、LDL-C、HDL-C、Apo A、Apo B及Lp(a)显著升高而TG无显著变化;左甲状腺素治疗显性与亚临床甲减均改善血脂谱,亚临床甲减改善幅度较小。
要点
- 治疗显性甲亢后TC升高44.50 mg/dL、LDL-C升高31.13 mg/dL,血脂谱恶化。
- 亚临床甲亢治疗未使任何血脂参数发生显著变化。
- 左甲状腺素治疗显性甲减使TC降低58.4 mg/dL、LDL-C降低41.11 mg/dL;亚临床甲减变化相似但幅度更小。
核心结论
- 治疗显性甲亢(而非亚临床甲亢)与血脂谱恶化相关。
- 左甲状腺素治疗显性和亚临床甲减均改善血脂谱,亚临床甲减改善幅度较小。
研究设计与样本
- 系统综述与荟萃分析,检索MEDLINE、EMBASE、Cochrane CENTRAL、Cochrane系统综述数据库及Scopus,时间1970年至2018年4月5日。
- 纳入评估甲亢或甲减治疗中血脂参数的随机研究和观察性研究,由成对独立评价者筛选、提取数据并评价研究。
主要发现
- 治疗显性甲亢:TC升高44.50 mg/dL(95%CI 37.99, 51.02),LDL-C升高31.13 mg/dL(95%CI 24.33, 37.93),HDL-C升高5.52 mg/dL(95%CI 1.48, 9.56),Apo A升高15.6 mg/dL(95%CI 10.38, 20.81),Apo B升高26.12 mg/dL(95%CI 22.67, 29.57),Lp(a)升高4.18 mg/dL(95%CI 1.65, 6.71),TG无显著变化。
- 治疗亚临床甲亢未使任何血脂参数发生显著变化。
- 显性甲减左甲状腺素治疗:TC降低58.4 mg/dL(95%CI -64.70, -52.09),LDL-C降低41.11 mg/dL(95%CI -46.53, -35.69),HDL-C降低4.14 mg/dL(95%CI -5.67, -2.61),TG降低7.25 mg/dL(95%CI -36.63, 17.87),Apo A降低12.59 mg/dL(95%CI -17.98, -7.19),Apo B降低33.96 mg/dL(95%CI 41.14, -26.77),Lp(a)降低5.6 mg/dL(95%CI -9.06, -2.14)。
- 亚临床甲减左甲状腺素治疗显示相似的血脂变化,但幅度较小。
关键数值与推荐
- 显性甲亢治疗后TC升高44.50 mg/dL(95%CI 37.99, 51.02),LDL-C升高31.13 mg/dL(95%CI 24.33, 37.93)。
- 显性甲减左甲状腺素治疗后TC降低58.4 mg/dL(95%CI -64.70, -52.09),LDL-C降低41.11 mg/dL(95%CI -46.53, -35.69)。
- 亚临床甲亢治疗未见任何血脂参数显著变化;亚临床甲减治疗血脂改善幅度小于显性甲减。
临床怎么用
- 管理甲亢患者时应关注治疗过程中血脂升高,尤其是显性甲亢治疗后。
- 对显性和亚临床甲减,左甲状腺素治疗可改善血脂谱,亚临床甲减改善幅度较小。
- 亚临床甲亢患者不应以改善血脂为目的进行抗甲状腺治疗。
局限性
- 纳入研究的人群特征、甲状腺功能异常严重程度及随访时间存在差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Hyperthyroidism is associated with low levels of cholesterol and triglycerides, and hypothyroidism is associated with hypercholesterolemia and hypertriglyceridemia. OBJECTIVE: The aim of this systematic review was to investigate the impact of therapy for overt and subclinical hyper- and hypothyroidism on serum lipids. DATA SOURCES: We searched MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials, the Cochrane Database of Systematic Reviews, and Scopus from 1970 through April 5, 2018. STUDY SELECTION: Pairs of independent reviewers selected randomized and observational studies evaluating lipid parameters in patients undergoing treatment for hyper- or hypothyroidism. DATA EXTRACTION: Pairs of independent reviewers extracted data and appraised studies. DATA SYNTHESIS: Treatment of overt hyperthyroidism showed a significant increase in total cholesterol (TC) by 44.50 mg/dL (95% confidence interval [CI]: 37.99, 51.02), low-density lipoprotein cholesterol (LDL-C) by 31.13 mg/dL (95% CI: 24.33, 37.93), high-density lipoprotein cholesterol (HDL-C) by 5.52 mg/dL (95% CI: 1.48, 9.56), apolipoprotein A (Apo A) by 15.6 mg/dL (95% CI: 10.38, 20.81), apolipoprotein B (apo B) by 26.12 mg/dL (95% CI: 22.67, 29.57), and lipoprotein (Lp[a]) by 4.18 mg/dL (95% CI: 1.65, 6.71). There was no significant change in triglyceride (TG) levels. Treatment of subclinical hyperthyroidism did not change any lipid parameters significantly. Levothyroxine therapy in overt hypothyroidism showed a statistically significant decrease in TC by -58.4 mg/dL (95% CI: -64.70, -52.09), LDL-C by -41.11 mg/dL (95% CI: -46.53, -35.69), HDL-C by -4.14 mg/dL (95% CI: -5.67, -2.61), TGs by -7.25 mg/dL (95% CI: -36.63, 17.87), apo A by -12.59 mg/dL (95% CI: -17.98, -7.19), apo B by -33.96 mg/dL (95% CI: 41.14, -26.77), and Lp(a) by -5.6 mg/dL (95% CI: -9.06, -2.14). Levothyroxine therapy in subclinical hypothyroidism showed similar changes but with a smaller magnitude. The studies contained varied population characteristics, severity of thyroid dysfunction, and follow-up duration. CONCLUSIONS: Treatment of overt but not subclinical hyperthyroidism is associated with worsening of the lipid profile. Levothyroxine therapy in both overt and subclinical hypothyroidism leads to improvement in the lipid profile, with a smaller magnitude of improvement in subclinical hypothyroidism.
引用
- Kotwal A, Cortes T, Genere N, et al. Treatment of Thyroid Dysfunction and Serum Lipids: A Systematic Review and Meta-analysis. J Clin Endocrinol Metab. 2020. PMID: 32954428. doi:10.1210/clinem/dgaa672
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。